 |
GRATTAN CROWE WOODSON, III, M.D.,
FACP
CURRICULUM VITAE
Office Address
2801 North Decatur Rd.
Suite 375
Decatur, Georgia 30033
Office Numbers
Voice: 404.298.9951
Facsimile: 404.298.5577
|
|
ACADEMIC AND PROFESSIONAL BACKGROUND
Northside High School,
Atlanta, Ga. 1970
Oglethorpe University,
Atlanta, Ga. BS 1976
Research Fellowship, Anatomic
Pathology, Medical College of Georgia 1978
Medical College of Georgia,
Augusta, Ga. M.D. 1980
Internship and Residency in
Internal Medicine MI Bassett Hospital, Cooperstown, NY 1980-83
Clinical Fellow in Medicine,
Columbia University College of Physicians and Surgeons, 1980-83
Senior Associate, Department
of Medicine, Emory University School of Medicine, 1983-86
Clinical Instructor of
Medicine, Emory University School of Medicine, 1986 - present
Attending Physician in
Internal Medicine, Atlanta Center for Medicine, 1986 - 97
Medical Director, Osteoporosis
Center of Atlanta, 1988 - present
Medical Director, Atlanta
Research Center, LLC 1989 - present
Attending Physician, DeKalb
Internal Medicine, LLC 1997 - present
PROFESSIONAL ORGANIZATIONS
Certified by the American
Board of Internal Medicine 1983
Fellow of the American College
of Physicians 1993
Member of the American Society
for Bone and Mineral Research since 1986
Member of the American Society
of Internal Medicine since 1988
President of the Georgia
Chapter of the National Osteoporosis Foundation, 1987-91
Member,The Southern Medical
Association since 1986
Member, The Paget’s Disease
Foundation since 1989
Member, The Osteogenesis
Imperfecta Foundation since 1991
Member of the Scientific
Advisory Board of the National Osteoporosis Foundation Washington,
DC 1989-1995
Education Committee,
Scientific Advisory Board of the National Osteoporosis
Foundation 1990-1995
Member of the Clinical Society
for Bone Densitometry since 1993
Co-Founder and Board Member of
OsNet Inc.: A Non-profit Clinical Research Network since 1995.
Member of the Southeastern
Regional Scientific Advisory Board of the Better Bones
Alliance, Proctor and Gamble Pharmaceuticals and Aventis, 1998 -
present
Member of the National
Internal Medicine Advisory Board, Eli Lilly and Company 2001 -
present
Member of the US Bazedoxifene
Steering Committee, Wyeth Research, 2002 – present
HOSPITAL AFFILIATION
DeKalb Medical Center,
Decatur, Georgia since 1986-present
CONTRACT RESEARCH EXPERIENCE
1985-1990
Coinvestgator
Sponsor: Norwich Eaton
Pharmaceuticals (Division of Proctor and Gamble)
Study: Etidronate
Multicenter Trial (PMOII)
Protocol: Coherence (ADFR)
therapy of osteoporosis with phosphate and etidronate: A multicenter,
randomized, double-blind trial.
Drug: Etidronate disodium
1990-1998
Principal Investigator
Sponsor: Sandoz
Pharmaceutical
Study: Miacalcin 320
Protocol: A multi-centered,
double-blind, placebo-controlled study to investigate the
efficacy of salmon calcitonin nasal spray in the prevention of
osteoporotic vertebral fractures.
Drug: Salmon calcitonin
nasal spray
1992-1997
Principal Investigator
Sponsor: Sanofi Winthrope
Study: Tiludronate 004
Protocol: A phase III study
of intermittent cyclical tiludronate in the treatment
of established post-menopausal osteoporosis.
Drug: Tiludronate
1992-1996
Principal Investigator
Sponsor: Sanofi Winthrope
Protocol: A phase III study
of intermittent cyclical tiludronate in the treatment of
post- menopausal women with low bone mineral mass and
no vertebral fractures.
Study: Tiludronate 005
Drug: Tiludronate
1993-1999
Principal Investigator
Study name: RHN
9193
Sponsor: Proctor and Gamble
Pharmaceuticals
Protocol: A multicenter,
randomized, double-blind, placebo-controlled parallel
group study to determine the efficacy and safety of risedronate
in the treatment of osteoporosis in elderly women.
Drug: Risedronate
1993-1995
Principal Investigator
Sponsor: Proctor and Gamble
Pharmaceuticals
Protocol: A randomized,
double-blind, placebo-controlled, multicenter, parallel group
study to determine the efficacy and safety of risedronate in the
treatment of postmenopausal osteopenic women.
Study: RON 9393
Drug: Risedronate
1995-1998
Principal Investigator
Sponsor: Merck Human Health
Protocol: A triple-blind,
randomized, placebo-controlled, parallel-group multicenter study
to evaluate the safety, tolerability and effect on bone mineral
density of 10mg of alendronate sodium for the treatment of
postmenopausal osteoporosis in elderly female long-term care
facility residents.
Study: FOS351
Drug: Alendronate Sodium
1996-2000
Principal Investigator
Sponsor: Roche
Protocol: Multi-center,
double-blind, placebo-controlled, randomized study on the
efficacy and safety of ibandronate during 3 years’ treatment in
patients with postmenopausal osteoporosis and vertebral
fractures using a continuous oral (2.5 mg daily) and an
intermittent oral (20 mg every 2nd day for 24 days
every 3 months) dosing regimen.
Study: MF 441
Drug: Ibandronate
1997-1999
Principal Investigator
Sponsor: Merck Human Health
Protocol: A triple-blind,
randomized, placebo-controlled multicenter study to compare
efficacy of oral alendronate sodium to intranasal calcitonin-salmon
for treatment of postmenopausal osteoporosis (IN-FOCAS).
Study: FOS 417
Drug: Alendronate Sodium
1997-1999
Principal Investigator
Sponsor: Purdue Pharma
Protocol: Safety and Efficacy of Buprenorphine TDS (Transdermal
Delivery System) 12.5, 25. and 50ug/hr Applied every Seven Days for
Sixty Days vs 5mg Oxycodone/325 mg acetomenophen Tablets q6h PRN vs
Placebo in Patients with Chronic Back Pain.
Study:
BP96-102
Drug:
Buprenorphine
1997-1999
Principal Investigator
Sponsor: Purdue Pharma
Protocol: A Long-Term, Open-Label, Clinical Use Safety Study of
Buprenorphine TDS (Transdermal Delivery System) 12.5, 25, and
50ug/hr Applied Every 72 hours for the Management of Ongoing Pain
Syndromes.
Study:
BP96-0103
Drug:
Buprenorphine
1998-1999
Principal Investigator
Sponsor: Purdue Pharma
Protocol: A Comparative Study of Buprenorphine TDS, Oxycodone/Acetomentophen
Tablets QID and Placebo in Patients with Chronic Back Pain
Study:
BP96-0604
Drug:
Buprenorphine
1998-2000
Principal Investigator
Sponsor: Pfizer
Protocol: Safety and efficacy of droloxifene for preventing bone
loss in normal, early postmenopausal women.
Study:
174-113
Drug:
droloxifene, raloxafen
1998-2000
Principal Investigator
Sponsor: Parke Davis
Protocol: A Randomized, Double-Blind, Active - and Placebo
Controlled, Parallel Group, Multicenter Study Assessing the Safety
and Protective Effect on the Endometrium of 4 Dosage Combinations of
Norethindrone Acetate Plus Ethinyl Estradiol.
Study:376-401
Drugs:
Ethinyl Estradiol and Norethindrone1997-98
1998-2000
Principal Investigator
Sponsor: Novartis
Protocol: A Double-Blind, Placebo Controlled Safety and Efficacy
Trial with Transdermal Zolendronate (CGP 42446) in the Treatment of
Postmenopausal Osteoporosis.
Study:18
Drug:
Zolendronate
1998-99
Principal Investigator
Sponsor: Merck Human Health
Protocol: A randomized, placebo and active comparator-controlled,
parallel group, double blind study to compare the efficacy and
safety of MK-0966 tablets vs. nabumetone tablets in patients with
osteoarthritis of the knee.
Drug:
MK-0966, (Vioxx) (rofecoxib, COX II inhibitor
1998-99
Principal Investigator
Sponsor: Berlex
Study:
96041-B
Protocol: A mulitcenter, double-blind, randomized, placebo
controlled, study to evaluate the safety and efficacy of two doses
of estradiol given by continuous transdermal administration in
prevention of osteoporosis in postmenopausal women.
Drug:
Estrogen and Progesterone
1999 – 2000
Principal Investigator
Sponsor: Bayer
Study:
#100011
Protocol: A multi-center, double blind, placebo controlled, group
comparison study to investigate the efficacy, tolerability and
safety of BAY 12,9566 as compared to placebo, in the treatment of
patients with mild to moderate osteoarthritis of the knee, over 3
years.
Drug:
BAY 12, 9566 (Metaloprotease inhibitor)
1999- 2002
Sub-Investigator
Sponsor: Parke Davis – Pfizer
Protocol: Beyond endorsed lipid lowering with EBCT scanning
Acronym: BELLES
Drug:
atorvastatin and pravastatin
1999- 2001
Sub-investigator
Protocol: A 20-week open-label assessment of the safety and efficacy
profile of atorvastatin when used to optimally control dyslipidemia
in postmenopausal patents.
Acronym: DUET( Atrovastatin Drug Utilization and Experience Trial
Sponsor: Park Davis – Pfizer
Drug:
atorvastatin
1999-2000
Principal Investigator
Protocol: Clinical Protocol for the Multicenter, Double-bind,
Parallel Group Study Comparing the Effects on Renal Function and the
Incidence of Gastrointestinal Ulcer Associated with Valdecoxib 20 mg
and 40 mg with that of Naproxen 500 mg bid in Patients with
Osteoarthritis or Rheumatoid Arthritis.
Sponsor: Searle
Drug:
valdecoxib and naproxen sodium
1999-2000
Principal Investigator
Protocol: A double-blind, randomized placebo-controlled,
multi-center study to evaluate upper gastrointestinal tolerability
upon rechallange in postmenopausal women with osteoporosis who
previously discontinued alendronate due to upper gastrointestinal
symptoms.
Sponsor: Merck
Drug:
alendronate
1999-2001
Principal Investigator
Protocol: A 12-week, randomized, partially-blinded, active and
placebo controlled, parallel group, multi-center study assessing the
effect of norethendrone acetate plus ethinyl estradiol on
endothelial dysfunction in postmenopausal women.
Sponsor: Parke Davis
Drug:
norethendrone and ethinyl estradiol
2000-2002
Principal Investigator
Protocol: A double-blind, randomized study of the safety and
efficacy of a combination of sulfonylurea and 30 mg of ACTOS (pioglitazone
HCl) in the treatment of patients with type 2 (non-insulin
dependent) diabetes mellitus.
Sponsor: Takada America R&D Inc.
Drug:
pioglitazone
2000-2001
Principal Investigator
Protocol: A randomized placebo-controlled, parallel group, double
blind study to evaluate the safety and efficacy of rofecoxib 12.5
mg, rofecoxib 25 mg, and celecoxib 200 mg n patients with
osteoarthritis of the knee or hip.
Sponsor: Merck Research Laboratories
Drug:
rofenoxib and celecoxib
2001-present
Principal Investigator
Protocol: A Multicenter, Double-Blind, Randomized, Placebo and
Raloxifene-Controlled Study to Assess Safety and Efficacy of TSE-424
in the Prevention of Postmenopausal Osteoporosis.
Sponsor: Wyeth Research
Drug:
Bazedoxifene Acetate/Raloxifene
2001-present
Principal Investigator
Protocol: Fracture Incidence Reduction and Safety of TSE-424 (Bazedoxifene
Acetate) Compared to Placebo and Raloxifene in Osteoporotic
Postmenopausal Women.
Sponsor: Wyeth Research
Drug:
Bazedoxifene Acetate/Raloxifene
2001-present
Principal Investigator
Protocol: Protocol Title: Comparison of Raloxifene to Alendronate in
Postmenopausal Women with Osteoporosis (H3S-US-GGKO)
Sponsor: Eli Lilly and Company
Drug:
Raloxifene and alendronate
2002-present
Principal Investigator
Protocol: A Double-Blind, Randomized, Placebo and Active Controlled
Safety and Efficacy Study of Bazedoxifene/Conjugated Estrogens
Combinations Postmenopausal Women.
Sponsor: Wyeth Research
Drug:
Bazedoxifene Acetate and Premarin/Raloxifene
2002-present
Principal Investigator
Protocol: A Randomized, Double-Blind, Placebo-controlled, Multi-Dose
Phase 2 Study to Determine the Efficacy, Safety, and Tolerability of
AMG 162 in the Treatment of Postmenopausal Women with Low Bone
Mineral Density.
Sponsor: Amgen
Drug:
AMG 162/Fosomax
2002-present
Principal Investigator
Protocol: Multinational, multicenter, double-blind, randomized,
placebo controlled, parallel group study assessing the efficacy of
intravenous zoledronic acid in preventing subsequent osteoporotic
fractures after a hip fracture.
Sponsor: Novartis
Drug:
Zoledronic Acid
Publications
D. Hewitt, G. Woodson, L. L.
Vacca A comparison of methods to localize peroxidase activity in
erythrocytes and immunoperoxidase procedures. GA J Science,
1978;3:101.
L. L. Vacca, D. Hewitt, G.
Woodson, A comparison of methods using diaminobenzidine (DAB) to
localize peroxidase in erythrocytes, neutrophils, and
peroxidase-antiperoxidase complex. Stain Tech, 1978;53:331-336.
G. Woodson, Coherence therapy
with phosphate and etidronate for osteoporosis: preliminary
results. in Osteoporosis 1987, Proceedings of the Second
International Symposium on Osteoporosis Aalborg, Denmark pp.
1188-1189
N. B. Watts, G. Woodson, S.
O'Neal, B.D. Catherwood Serum bone Gamma-carboxyglutamate-
containing protein (BGP) declines with time after menopause but
does not correlate with age. Abstract, Clinical Research,
1989;37.
G. Woodson, Coherence therapy
increases bone mass. Abstract, J Bone Min Res 1989: Supp 1.
N. B. Watts, S. T. Harris, H.
K. Genant, R. D. Wasnich, P. D. Miller, R. D. Jackson, A. A.
Licata, P. D. Ross, G. C. Woodson, M. J. Yanover, W. J. Mysiw, L.
Kohse, M. B. Rao, P. Steiger, B. Richmond, C. H. Chestnut,
Intermittent cyclical etidronate treatment of postmenopausal
osteoporosis. N Eng J Med 1990;323;73-79.
G. Woodson, Etidronate
combined with estrogen increases bone mass in osteopenia and
osteoporosis. in Osteoporosis 1990, Proceedings of the third
International Symposium on Osteoporosis Copenhagen, Denmark 14-20
October 1990 Eds Claus Christiansen and Kirsten Overgaard, pp
1476-1478.
S. M. Ott, G. C. Woodson, W.
E. Huffer, Bone histomorphometric changes in women with
postmenopausal osteoporosis treated with etidronate. in
Osteoporosis 1990, Proceedings of the Third International
Symposium on Osteoporosis Copenhagen, Denmark 14-20 October 1990
Eds Claus Christiansen and Kirsten Overgaard, pp 1318-1322.
G. Woodson, Carlson LM,
Treating osteoporosis: the etidronate option. Senior Patient
1991;3:8-15.
S.M. Ott, G. C. Woodson, W.E.
Hufer, P.D. Miller, N.B. Watts, Effects of etidronate and
phosphate on bone histomorphology in women with postmenopausal
osteoporosis. Abstract # 561, J Bone Min Res August 1991 (supp 1)
pp s224.
G. Woodson, Three effective
treatments for osteoporosis. Abstract presented at the Adult Bone
and Mineral Working Group of the ASBMR, Tampa Sept 1993, J Bone
Min Res 1993;s403.
Susan M. Ott, Grattan C.
Woodson, William E. Huffer, Paul D. Miller, Nelson B. Watts, Bone
histomorphometric changes after cyclic therapy with phosphate and
etidronate disodium in women with postmenopausal osteoporosis. J
Clin Endocrinol Metab 1994;78:968-972.
Woodson,G., Phosphate
depletion, osteomalacia, and aluminum intoxication due to antacid
use in a patient with normal renal function. Oral presentation at
the Adult Bone and Mineral Group of the ASBMR, Baltimore, MD
September 1995. J Bone Min Res 1995:(supp 1):
Woodson,G., Adequate screening
for axial osteoporosis with densitometry requires measurement of
the hip and spine. Poster presentation at the ASBMR, Baltimore,
MD September 1995. J Bone Min Res 1995;(supp 1):
M McClung, W Benson, M
Bolognese, S Bonnick, M Ettinger, S Harris, H Heath, R Lang , P
Miller, E Pavlov, S Silverman, G Woodson, K Kalkner, P Bekker,.
Risedronate treatment of postmenopausal women with low bone mass:
Preliminary Data. Osteoporosis Int 1996; (suppl 1):PTu 700
Woodson, GC.,. An effectiveness study of
etidronate therapy with and without estrogen. J Bone Min Res
1996;(supp 1):M651
P Beeker, M McClung, W Benson,
M Bolognese, S Bonnick, M Ettinger, S Harris, H Heath, R Lang , P
Miller, E Pavlov, S Silverman, GC Woodson, K Kalkner, D Axelrod,.
Risedronate is effective in increasing BMD in both early and late
postmenopausal women with low bone mass. J Bone Min Res
1997;(suppl 1): S474
McClung, M, W Benson, M
Bolognese, S Bonnick, M Ettinger, S Harris, H Heath, R Lang , P
Miller, E Pavlov, S Silverman, GC Woodson, K Kalkner, P Bekker, D
Axelrod,. Risedronate increases BMD at the hip and spine in
postmenopausal women with low bone mass. J Bone Min Res
1997;(suppl 1): P269
Woodson, GC., The diagnosis of osteoporosis using
the NHANES II Vs the Hologic normative data for the femoral neck.,
J Bone Min Res 1997;(suppl 1): S531
Woodson, GC., The supine
lateral site is more sensitive for the diagnosis of osteoporosis
than other axial DXA sites. J Bone Min Res 1997;(suppl 1): F614
Woodson, GC., An interesting
case of osteomalacia due to antacid use associated with stainable
bone aluminum in a patient with normal renal function. Bone 1998;
22:6;695-985.
Silverman S, Genant HK, Kiel
DP, Maricic MJ, Peacock M, Woodson GC., Salmon-Calcitonin nasal
spray prevents fractures in established osteoporosis. Additional
interim fracture analysis of the “PROOF” study. 1998 Bone;
23(suppl 5)
Chestnut C, Maricic MJ,
Silverman S, Woodson GC., Are bone mineral density and biomarkers
good predictors of efficacy for prevention of osteoporotic
fractures? – Salmon-calcitonin nasal spray and alendronate. 1998
Bone; 23(suppl 5)
Woodson GC, DXA T-score
Concordance and Discordance between the PA Spine and the Total Hip
Sites. (Oral presentation ASBMR 10-1-99, St Louis, MO) 1999, JBMR
14;suppl 1:#1027, S139
Rosen CJ, Bonnick SL, Miller
PD, McClung MR, Wasnich RD, Weiss SR, Woodson GC, Schnitzer TJ,
Lenihan JP, Ross RP, Wang L, Smith ME, Gormley GJ, Melton, ME.,
Treatment of osteoporosis in postmenopausal women: alendronate vs
intranasal spray calcitonin (effect on bone markers). 1999, JBMR
14;suppl 1:# SA 364, S399.
Rosen CJ, Bonnick SL, Miller
PD, McClung MR, Wasnich RD, Weiss SR, Woodson GC, Schnitzer TJ,
Lenihan JP, Ross RP, Wang L, Smith ME, Gormley GJ, Melton, ME., .,
Treatment of osteoporosis in postmenopausal women: alendronate vs
intranasal spray calcitonin (effect on BMD) 1999, JBMR 14;suppl
1:# S365, S400.
Fogelman I, Moreland L,
Woodson GC, Mellstrom D, Boling E, Riskin W, Strauss D, Stevens K,
Manhart M., Gastrointestinal side effects and endoscopic
findinings similar between risedronate and placebo-treated
patients. 2000 Osteoprosis Int (Suppl 2)1179;459
Woodson GC., Once Weekly
Risedronate Therapy. 2000, Osteoporosis Int (suppl 2) s204, 550
Hooper M, Hanley D, Eastell R,
Boling B, Ribot C, Woodson GC, Barton I., Sustained Effect of
Risedronate in the Prevention of the First Vertebral Fracture in
Women. 2000, JBMR (suppl 1) SU400, s428
Josse R, Fogelman I, Woodson
GC, Boling E, Stevens K,. Gastrointestinal side effects and
endoscopic findings similar between risedronate and placebo
treated patients. 2000, Presented at the Endocrine Society
Meeting, Toronto, CA on 6-12-2000
Woodson, GC., T-score
concordance and discordance between the hip and spine measurement
sites. J. Clinical Densitometry, 2000;3:319-324.
Miller P, Woodson GC, Licata
AA, Ettinger MP, Mako B, Smith ME, Wang L, Yates J, Melton ME,
Pamisano JJ,. Rechallange of patients who had discontinued
alendronate therapy because of upper gastrointestinal symptome.
2000, Clin Ther 22;1433-1422.
|
 |
